Compare Ascendis Pharma A/S (ASND) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $434.15 (market cap $1.96T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 110.5× Ascendis Pharma A/S's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.87% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TSM | |
|---|---|---|
Market Cap | $17.74B | $1.96T |
Sector | Health | Technology |
52-Week High | $277.18 | $477.57 |
52-Week Low | $163.32 | $227.33 |
Enterprise Value | $18.11B | $1.88T |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TSM trades at $434.11, down 0.65% on the day, with a neutral technical signal. The stock shows strong fundamentals, with revenue growing to $3.81 trillion in 2025 and a net income margin of 46.5%. Analyst consensus is strongly bullish with a $493.75 price target, supported by consistent earnings beats and robust cash flow generation. Recent news highlights upcoming earnings on July 16 as a potential catalyst amid elevated AI-driven demand.
The outlook for TSM remains positive given its dominant market position and earnings momentum, though risks include competitive pressures and semiconductor cycle volatility. The stock offers growth potential aligned with AI infrastructure expansion, but investors should weigh valuation multiples against execution risks in a dynamic industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →
